| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -93,841 | - |
| Stock-based compensation expense | 10,147 | - |
| Depreciation and amortization | 277 | - |
| Amortization of debt issuance costs and discounts | 8,101 | - |
| Net amortization of premiums and discounts on investments | 401 | - |
| Gain on extinguishment of debt | 0 | - |
| Change in fair value of embedded derivatives and common stock warrants | 10,596 | - |
| Accounts receivable, net | 1,111 | - |
| Inventory | -773 | - |
| Prepaid expenses and other assets | -4,219 | - |
| Operating lease right-of-use assets | -1,204 | - |
| Accounts payable | 285 | - |
| Accrued expenses and other liabilities | 17,622 | - |
| Operating lease liabilities | -220 | - |
| Net cash used in operating activities | -63,541 | - |
| Proceeds from maturities of investments | 38,378 | - |
| Purchases of investments | 0 | - |
| Purchases of property and equipment | 0 | - |
| Net cash provided by investing activities | 38,378 | - |
| Proceeds from issuance of senior secured term loan | 0 | - |
| Proceeds from the exercise of stock options and shares issued under the employee stock purchase plan | 356 | - |
| Payment of debt issuance costs | 0 | - |
| Payment of deferred royalty obligation | 0 | - |
| Net cash provided by financing activities | 356 | - |
| Long-term restricted cash | - | 350 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | 15 | - |
| Short-term restricted cash | - | 0 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -24,792 | - |
| Cash and cash equivalents | - | 38,725 |
| Cash and cash equivalents at beginning of period | 62,814 | - |
| Cash and cash equivalents at end of period | 38,022 | 39,075 |
Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. (KPTI)